Research programme: spinal cord injury therapies - Protherics

Drug Profile

Research programme: spinal cord injury therapies - Protherics

Alternative Names: Nanotechnology therapies

Latest Information Update: 23 Nov 2009

Price : $50

At a glance

  • Originator Protherics
  • Class
  • Mechanism of Action Nerve growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Spinal cord injuries

Most Recent Events

  • 02 Dec 2003 Preclinical trials in Spinal cord injuries in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top